SCHEMBL1128760

SCHEMBL1128760

Cc1cc(Oc2ccccc2)ccc1B1OC(C)(C)C(C)(C)O1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 3/20 0.44
PDE4B Q07343 3/20 0.44
PDE4C Q08493 3/20 0.44
PDE4D Q08499 3/20 0.44
LPL P06858 2/20 0.39
LIPG Q9Y5X9 2/20 0.39
LIPE Q05469 2/20 0.39
LTA4H P09960 4/20 0.38
MMP2 P08253 1/20 0.38
MMP3 P08254 1/20 0.38
MMP9 P14780 1/20 0.38
MMP8 P22894 1/20 0.38
MMP13 P45452 1/20 0.38
ACHE P22303 1/20 0.38
MAOB P27338 2/20 0.36
TSHR P16473 1/20 0.36
MAOA P21397 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
ALDH1A1 P00352 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16023893 0.87 PDE4B (0.46) PDE4APDE4BPDE4CPDE4DLPL
SCHEMBL29792085 0.84 PDE4A (0.43) PDE4APDE4BPDE4CPDE4DLPL
SCHEMBL13860167 0.84 PDE4A (0.43) PDE4APDE4BPDE4CPDE4DLPL
SCHEMBL4357613 0.84 PDE4A (0.43) PDE4APDE4BPDE4CPDE4DLPL
SCHEMBL30143835 0.84 PDE4A (0.43) PDE4APDE4BPDE4CPDE4DLPL
SCHEMBL23030124 0.83 PDE4B (0.49) PDE4APDE4BPDE4CPDE4DLIPE
SCHEMBL1129675 0.82 LTA4H (0.43) PDE4APDE4BPDE4CPDE4DLPL
SCHEMBL1129617 0.81 PDE4A (0.42) PDE4APDE4BPDE4CPDE4DLPL
SCHEMBL7162404 0.81 SNCA (0.42) PDE4APDE4BPDE4CPDE4DLPL
SCHEMBL1128925 0.80 LIPE (0.43) PDE4APDE4BPDE4CPDE4DLPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023122778-A1 PYRIDAZINONE DERIVATIVES USEFUL AS T CELL ACTIVATORS GOSSAMER BIO SERVICES, INC. (US) 2023-06-29 WO disclosed
US-11155544-B2 Heterocycle comprising tyrosine kinase inhibitors PRINCIPIA BIOPHARMA INC. (US) 2021-10-26 US disclosed
US-20190345159-A1 TYROSINE KINASE INHIBITORS PRINCIPIA BIOPHARMA INC. (US) 2019-11-14 US disclosed
US-20180305350-A1 TYROSINE KINASE INHIBITORS PRINCIPIA BIOPHARMA INC. (US) 2018-10-25 US disclosed
EP-3313839-A1 TYROSINE KINASE INHIBITORS Principia Biopharma Inc. (US) 2018-05-02 EP disclosed
WO-2016210165-A1 TYROSINE KINASE INHIBITORS PRINCIPIA BIOPHARMA INC. (US) 2016-12-29 WO disclosed
US-8481733-B2 Substituted imidazopyr- and imidazotri-azines OSI Pharmaceuticals, LLC (US) 2013-07-09 US disclosed
EP-2283020-B1 SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES OSI PHARM INC (US) 2012-10-31 EP disclosed
EP-2283020-A1 SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES OSI Pharmaceuticals, Inc. (US) 2011-02-16 EP disclosed
WO-2009143051-A1 SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES OSI PHARMACEUTICALS, INC. (US) 2009-11-26 WO disclosed
US-20090286768-A1 SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES OSI PHARMACEUTICALS, INC. (US) 2009-11-19 US disclosed
US-6713474-B2 SERINE-THREONINE AND TYROSINE KINASE INHIBITORS ABBOTT GMBH & CO. KG (DE) 2004-03-30 US disclosed
US-20030153752-A1 Pyrrolopyrimidines as therapeutic agents ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2003-08-14 US disclosed
WO-2001072751-A1 PYRROLOPYRIMIDINES AS TYROSINE KINASE INHIBITORS KNOLL GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) 2001-10-04 WO disclosed
EP-1114053-A1 PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS BASF AKTIENGESELLSCHAFT (DE) 2001-07-11 EP disclosed
WO-2000017203-A1 PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS BASF AKTIENGESELLSCHAFT (DE) 2000-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190345159-A1 TYROSINE KINASE INHIBITORS BTK, SYK, LCK PDE4A 1682/4885PDE4B 1878/4885PDE4C 1408/4885
US-20030153752-A1 Pyrrolopyrimidines as therapeutic agents FLT1, FLT4, TFPI PDE4A 2357/4885PDE4B 2286/4885PDE4C 2502/4885
US-11155544-B2 Heterocycle comprising tyrosine kinase inhibitors BTK, SYK, LYN PDE4A 1785/4885PDE4B 1843/4885PDE4C 1223/4885
US-20180305350-A1 TYROSINE KINASE INHIBITORS BTK, SYK, LCK PDE4A 1682/4885PDE4B 1878/4885PDE4C 1408/4885
US-20090286768-A1 SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES ABL1, TPMT, CYP2C19 PDE4A 1037/4885PDE4B 1682/4885PDE4C 1999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.